Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $25.60 Consensus Price Target from Brokerages

Key Points

• Maze Therapeutics, Inc. has received an average analyst recommendation of "Buy" from seven firms, with a consensus price target of $25.60.
• Recent investments in Maze include significant new positions from various hedge funds, with total amounts several nearing $80,000.
• Despite its promising ratings, Maze reported losses of ($1.15) EPS, which fell short of analyst expectations of ($0.76).

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) has received an average rating of "Buy" from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $25.60.

A number of equities analysts have commented on the company. HC Wainwright began coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Wedbush assumed coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company.

Maze Therapeutics Stock Down 3.6%

MAZE traded down $0.52 on Friday, hitting $13.99. 42,478 shares of the company traded hands, compared to its average volume of 203,334. The stock's 50 day moving average is $13.76. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC bought a new stake in Maze Therapeutics during the second quarter valued at approximately $28,000. New York State Common Retirement Fund bought a new position in Maze Therapeutics in the 1st quarter worth about $25,000. Corebridge Financial Inc. bought a new position in Maze Therapeutics in the 1st quarter worth about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Maze Therapeutics during the 1st quarter valued at about $57,000. Finally, Rhumbline Advisers bought a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $80,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.